Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that the United States Adopted Names (USAN) Council has approved the name narmafotinib as the nonproprietary drug name for Amplia Therapeutics' lead FAK inhibitor.

The timing coincides with the imminent initiation of a clinical trial in pancreatic cancer of narmafotinib combined with the chemotherapy FOLFIRINOX to be conducted in Australia and the USA.

Amplia’s CEO and Managing Director Dr Chris Burns commented:

“We are delighted that the USAN council have adopted the name narmafotinib. Obtaining a USAN is an essential step for any drug molecule intended for the US market, and it represents an important step in the drug’s commercial development as we begin our trial of narmafotinib in the USA.”

Narmafotinib adopted as nonproprietary drug name in USA